<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325126</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU 2020 G-66</org_study_id>
    <nct_id>NCT04325126</nct_id>
  </id_info>
  <brief_title>Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications</brief_title>
  <acronym>RMTACC</acronym>
  <official_title>Retinol-binding Protein 4 (RBP4) Metabolizm in Type 2 Diabetes Progression and Associated Cardiovascular Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinol-binding protein 4 (RBP4) may affects obesity development and the development of&#xD;
      obesity-related diseases including insulin resistance, type 2 diabetes, steatohepatitis and&#xD;
      cardiovascular disease. This study aims to examine the involvement of RBP4 in patients with&#xD;
      diagnosed diabetes, diabetic cardiovascular disease, pre-diabetes (pre-DM) and healthy&#xD;
      controls during the progression of T2DM, and to evaluate the ability of RBP4 to predict cases&#xD;
      of diabetes with an elevated risk of cardiovascular complications . Along with animal&#xD;
      experiment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong&#xD;
      University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the&#xD;
      RBP4 profles. Peripheral blood samples are drawn at the initial medical examination, in the&#xD;
      morning after a fast of at least 8 h, and immediately stored at -80˚C until the sphingolipid&#xD;
      measurements were performed.&#xD;
&#xD;
      Blood pressure, WC, hip circumference (HC), body weight and body height were measured by a&#xD;
      trained physician. The participants enrolled in the study provided written informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum RBP4 level</measure>
    <time_frame>2022.3</time_frame>
    <description>serum RBP4 level in DM, pre-DM, CVD, DM-CVD and healthy controls.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>RBP4 in diabetes</arm_group_label>
    <description>RBP4 in diagnosed diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBP4 in pre-diabetes (pre-DM)</arm_group_label>
    <description>RBP4 in pre-diabetes (pre-DM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBP4 in DM-CVD</arm_group_label>
    <description>RBP4 in diabetic cardiovascular disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBP4 in CVD</arm_group_label>
    <description>RBP4 in single coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBP4 in NC</arm_group_label>
    <description>RBP4 in healthy controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exposure factors</intervention_name>
    <description>Exposure factors，such as diet，exercise，environment</description>
    <arm_group_label>RBP4 in CVD</arm_group_label>
    <arm_group_label>RBP4 in DM-CVD</arm_group_label>
    <arm_group_label>RBP4 in NC</arm_group_label>
    <arm_group_label>RBP4 in diabetes</arm_group_label>
    <arm_group_label>RBP4 in pre-diabetes (pre-DM)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong&#xD;
      University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate the&#xD;
      RBP4 profles. Peripheral blood samples were drawn at the initial medical examination, in the&#xD;
      morning after a fast of at least 8 h, and immediately stored at -80˚C until the sphingolipid&#xD;
      measurements were performed.The participants enrolled in the study provided written informed&#xD;
      consent.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 500 Chinese patients admitted to the First Affliated Hospital of Xi'an Jiaotong&#xD;
        University (Xi'an, China) between March 2020 and March 2022 were recruited to investigate&#xD;
        the RBP4 profles. The different groups were matched for age, sex and BMI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        T2DM:&#xD;
&#xD;
          -  Fasting plasma glucose (FPG)≥7.0 mmol/l;&#xD;
&#xD;
          -  2 h plasma glucose (2hPG) ≥11.1 mmol/l;&#xD;
&#xD;
          -  glycated hemoglobin (HbA1c) level ≥6.5%;&#xD;
&#xD;
          -  random plasma glucose ≥11.1 mmol/l plus symptoms of hyperglycemia;&#xD;
&#xD;
          -  T2DM diagnosed previously.&#xD;
&#xD;
        Pre-DM was defned as follows:&#xD;
&#xD;
          -  FPG ≥5.6-6.9 mmol/l&#xD;
&#xD;
          -  2hPG 7.8-11.0 mmol/l&#xD;
&#xD;
          -  HbA1c 5.7-6.4%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  type 1 diabetes&#xD;
&#xD;
          -  liver or kidney disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Sui, doctor</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Sui, doctor</last_name>
    <phone>0086-18991989230</phone>
    <email>suijing1029@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Sui, doctor</last_name>
    <phone>0086-029-85324771</phone>
    <email>suijing1029@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Sui, doctor</last_name>
      <phone>0086-18991989230</phone>
      <email>suijing1029@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

